In October, Eli Lillys Zepbound and Mounjaro were removed from the drug shortage list after nearly two years, though the FDA warned that there still may be intermittent localized supply disruptions. The removal from the listwhich bars outsourcing facilities from producing compounded versionsspurred the Outsourcing Facilities Association to file a lawsuit against the FDA, saying the move will deprive much of the public of access to a needed medicine. In response, the FDA agreed to reevaluate the situation and will allow compounding to continue during this period
For the new study, researchers analyzed data for knee replacement patients with type 2 diabetes who had been taking semaglutide for varying amounts of time as little as less than a month, as long as up to a year
This question has a simple answer that people consistently overcomplicate
Why the Comparison is Still Incomplete This is the part many summary articles skip: no direct randomized head-to-head trial is currently available in the published literature comparing retatrutide with tirzepatide on the same protocol, in the same population, over the same duration
This proactive approach can help in managing side effects effectively and maintaining a stable condition
Addition of O 2 (final concentration, 0.1 mM) to a solution of DEPMPO (10 mM) in 0.1 M phosphate buffer (Fig